Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121105
Filing Date
2024-11-05
Accepted
2024-11-05 09:10:55
Documents
58
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crsp-20240930.htm   iXBRL 10-Q 1824664
2 EX-10.1 crsp-ex10_1.htm EX-10.1 138472
3 EX-31.1 crsp-ex31_1.htm EX-31.1 11612
4 EX-31.2 crsp-ex31_2.htm EX-31.2 11692
5 EX-32.1 crsp-ex32_1.htm EX-32.1 10350
  Complete submission text file 0000950170-24-121105.txt   7231871

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20240930.xsd EX-101.SCH 908251
60 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20240930_htm.xml XML 1310218
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37923 | Film No.: 241425947
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)